Manus Bio receives additional funding to combat malaria
Fourth award from the Bill & Melinda Gates Foundation will support artemisinin research
Manus Bio – the leading biomanufacturer of natural products – has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial therapy, artemisinin.
The $2m award will enable Manus Bio to begin scaling up the unique biological process it has developed towards the key chemical intermediate, dihydroartemisinic acid. Economical and scalable access to this compound will enable process simplification for large-scale commercial manufacturing of artemisinin.
Artemisinin is an effective compound in malaria treatments. The World Health Organization recommends artemisinin or one of its derivatives formulated in combination therapies as frontline treatments for all cases of malaria.
It has traditionally been extracted from the ‘Artemisia annua’, however, availability of the plant is subject to agricultural instabilities and vulnerabilities. The artemisinin precursor, dihydroartemisinic acid, can alternatively be produced using fermentation, which provides a more stable and sustainable source for making artemisinin than through agricultural extraction.
Read more: https://www.pharmatimes.com/news/manus_bio_receives_additional_funding_to_combat_malaria_1454225
Manus Bio – the leading biomanufacturer of natural products – has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial therapy, artemisinin.
The $2m award will enable Manus Bio to begin scaling up the unique biological process it has developed towards the key chemical intermediate, dihydroartemisinic acid. Economical and scalable access to this compound will enable process simplification for large-scale commercial manufacturing of artemisinin.
Artemisinin is an effective compound in malaria treatments. The World Health Organization recommends artemisinin or one of its derivatives formulated in combination therapies as frontline treatments for all cases of malaria.
It has traditionally been extracted from the ‘Artemisia annua’, however, availability of the plant is subject to agricultural instabilities and vulnerabilities. The artemisinin precursor, dihydroartemisinic acid, can alternatively be produced using fermentation, which provides a more stable and sustainable source for making artemisinin than through agricultural extraction.
Read more: https://www.pharmatimes.com/news/manus_bio_receives_additional_funding_to_combat_malaria_1454225
